United States Food and Drug Administration (United States Food and Drug Administration)FDA for its abbreviation in English) authorized this Friday a New treatment for Alzheimer’s This is intended to reduce cognitive decline in patients suffering from neurodegenerative diseases.
new treatmentWhich will be marketed by the pharmaceutical company Christian under name this group, It is recommended by the FDA for patients who have not yet reached an advanced stage of the disease.
Active principle of drug authorized against Alzheimer’s by FDA has been enrolled leknemaB, and attacks deposits of a protein called beta-amyloid.
The FDA’s approval is based on the results of clinical trials showing that The drug helped reduce amyloid plaques.
And it is that, although little is known about the cause of Alzheimer’s disease; Patients present with amyloid plaques in the brain, which build up around neurons and eventually destroy them. This causes the memory loss characteristic of the disease.
Studies in nearly 1,800 people who were followed for 18 months revealed a 27% reduction in cognitive decline in patients treated with lecanumab.
However, clinical trials also show serious adverse effects: Some treated patients had problems cerebral hemorrhage, In addition, at least one person receiving the treatment died, so the FDA included a warning about bleeding risk In drug information.
Upon approval, the FDA said in a statement that “this drug” represents an important step forward in our fight to effectively treat Alzheimer’s disease.
this is the second FDA-Approved Alzheimer’s Treatmentafter adhelm in June 2021 (which uses a molecule called aducanumab).
but the release of adhelm Didn’t get the expected success. Its authorization sparked controversy, as some experts criticized the lack of evidence on its effectiveness. Later, its use was restricted to people with moderate cases of the disease.